- Email: [email protected]
PD
366
Abstracts / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375
Ovarian carcinoma detection by spectrofluorimetry using a folate-targeted photosensitizer Soraya Khodja Bach 1,2 , Jean-Baptiste Tylcz 1 , Henri Azaïs 1,2 , Pierre Collinet 1,2 , Serge Mordon 1 , Nacim Betrouni 1
oxygenation (ECMO) to ensure ventilation. On the following day, ECMO was removed and the patient was extubated. After PDT, he underwent radiotherapy for rib and distal trachea. Follow-up bronchoscopy showed only fibrous scar at PDT site. The patient has been disease-free for 3 years and 9 months. From this case, Radachlorin® seems to be feasible and safe modality for managing central airway obstruction by lung cancer.
1
INSERM, U1189 – ONCO-THAI, University of Lille, 59000 Lille, France 2 Department of Gynecology, University of Lille, 59000 Lille, France Advanced ovarian cancer outcomes remain low. One of the reasons is that subclinical carcinomatosis lesions are difficult to detect and could be responsible for the high rate of peritoneal recurrences observed after optimal treatment (complete cytoreductive surgery and platinum-based chemotherapy). This study relies on folate receptor overexpression in 95% of epithelial ovarian cancers, which can be targeted by a photosensitizer to allow a better detection and so to improve completion of cytoreductive surgery Intra-peritoneal injections of folate-targeted tetraphenylporphyrin (Porph-s-FA) were performed on a validated ovarian carcinomatosis rat model. After 4 h, fluorescence was measured on lesions and healthy peritoneum by spectrofluorimetry. A statistical difference of fluorescence index was noticed between cancerous and healthy tissues (p = 0.03). The observed results confirm the molecule selectivity and indicate that such a targeted approach may improve ovarian carcinoma detection and prognosis by developing specific photodiagnosis and photodynamic therapy applications. http://dx.doi.org/10.1016/j.pdpdt.2015.07.159 A case of successfully treated airway obstruction using Radachlorin® PDT in advanced lung cancer Bo young Lee 1 , Jae Cheol Lee 2 , Hyeong Ryul Kim 3 , Seung Hun Jang 4 , Chang-Min Choi 1
http://dx.doi.org/10.1016/j.pdpdt.2015.07.160 Fluorescence image guided resection of glioblastoma multiforme: A metanalysis of the literature Samy Eljamel Consultant Neurological Surgeon and Chairman at HTNMS, United Kingdom Glioblastoma multiforme (GBM) is one of the most deadly cancers in humans. Despite recent advances in anti-cancer therapies, most patients with GBM die from local disease progression. Fluorescence image guided surgical resection (FIGR) was recently advocated to enhance local control of GBM. This is a meta-analysis of 5-aminolevulenic (5ALA) induced FIGR. Review of the literature produced 503 potential publications; only 20 of these fulfilled the inclusion criteria of this analyses, including a total of 565 patients treated with 5ALA-FIGR reporting on its outcomes and 800 histological samples reporting 5ALA-FIGR sensitivity and specificity. The mean gross total resection (GTR) rate was 75.4% (95%CI 67.4–83.5, p < 0.001). The mean time to tumor progression (TTP) was 8.1 months (95%CI 4.7–12, p < 0.001). The mean overall survival gain reported was 6.2 months (95%CI −1 to 13, p < 0.001). The specificity was 88.9% (95%CI 83.9–93.9, p < 0.001) and the sensitivity was 82.6% (95%CI 73.9–91.9, p < 0.001). 5ALA-FIGR in GBM is highly sensitive and specific, and imparts significant benefits to patients in terms of improved GTR, TTP, and overall survival. http://dx.doi.org/10.1016/j.pdpdt.2015.07.161
1
Department of Pulmonary and Critical Care medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Division of Thoracic Surgery, Republic of Korea 3 Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 4 Division of Pulmonary, Allergy and Critical Care medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea Photodynamic therapy (PDT) is proven to be effective not only in early, superficial lung cancer but also in advanced lung cancer. Radachlorin® is a second generation photosensitizer with improved pharmacokinetics. Here, we report a case of advanced lung cancer successfully treated with PDT. A 16 year-old boy complained of cough and blood tinged sputum but chest X-ray showed no abnormal finding. Over 2 months, symptoms were aggravated and hemoptysis developed. CT scan displayed the complete luminal obstruction of right main bronchus near carina by mass lesion. Bronchoscopic biopsy confirmed undifferentiated carcinoma. PET scan showed left 8th rib metastasis. Because the tumor was very closely located near carina, surgery was not amenable. Therefore, photodynamic therapy with Radachlorin® (1 mg/kg on the day of PDT) was performed under the support extracorporeal membrane
The future of PDT/PD Brian C. Wilson 1 , Tayyaba Hasan 2 1 2
University of Toronto, Canada Harvard Medical School, USA
Photodynamic therapy (PDT) and diagnosis (PDD, including both diagnostics per se and fluorescence-guided therapeutics) have been a substantial focus for research and development for several decades, so it is timely to ask the questions: why are these techniques not more prominent in routine clinical practice?; why has there not been a “home run” in cancer as there was in PDT for age-related macular degeneration?, what roles might they evolve into?; what scientific, technological, regulatory, clinical, cultural, geographic and commercial challenges must be overcome to establish them as part of the oncologic armamentarium offered to patients? The purpose of this presentation is to stimulate discussion among the developers (physicists, engineers, chemists, materials scientists, biologists) to explore how to integrate their individual contributions into effective and cost-effective complete clinical solutions, between clinical specialists to determine the best indications for these techniques and how to interdigitate them with other established and emerging modalities, and between all players to get PDT and PDD deployed to the maximum possible benefit of patients. http://dx.doi.org/10.1016/j.pdpdt.2015.07.162
Abstracts / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375
Ovarian carcinoma detection by spectrofluorimetry using a folate-targeted photosensitizer Soraya Khodja Bach 1,2 , Jean-Baptiste Tylcz 1 , Henri Azaïs 1,2 , Pierre Collinet 1,2 , Serge Mordon 1 , Nacim Betrouni 1
oxygenation (ECMO) to ensure ventilation. On the following day, ECMO was removed and the patient was extubated. After PDT, he underwent radiotherapy for rib and distal trachea. Follow-up bronchoscopy showed only fibrous scar at PDT site. The patient has been disease-free for 3 years and 9 months. From this case, Radachlorin® seems to be feasible and safe modality for managing central airway obstruction by lung cancer.
1
INSERM, U1189 – ONCO-THAI, University of Lille, 59000 Lille, France 2 Department of Gynecology, University of Lille, 59000 Lille, France Advanced ovarian cancer outcomes remain low. One of the reasons is that subclinical carcinomatosis lesions are difficult to detect and could be responsible for the high rate of peritoneal recurrences observed after optimal treatment (complete cytoreductive surgery and platinum-based chemotherapy). This study relies on folate receptor overexpression in 95% of epithelial ovarian cancers, which can be targeted by a photosensitizer to allow a better detection and so to improve completion of cytoreductive surgery Intra-peritoneal injections of folate-targeted tetraphenylporphyrin (Porph-s-FA) were performed on a validated ovarian carcinomatosis rat model. After 4 h, fluorescence was measured on lesions and healthy peritoneum by spectrofluorimetry. A statistical difference of fluorescence index was noticed between cancerous and healthy tissues (p = 0.03). The observed results confirm the molecule selectivity and indicate that such a targeted approach may improve ovarian carcinoma detection and prognosis by developing specific photodiagnosis and photodynamic therapy applications. http://dx.doi.org/10.1016/j.pdpdt.2015.07.159 A case of successfully treated airway obstruction using Radachlorin® PDT in advanced lung cancer Bo young Lee 1 , Jae Cheol Lee 2 , Hyeong Ryul Kim 3 , Seung Hun Jang 4 , Chang-Min Choi 1
http://dx.doi.org/10.1016/j.pdpdt.2015.07.160 Fluorescence image guided resection of glioblastoma multiforme: A metanalysis of the literature Samy Eljamel Consultant Neurological Surgeon and Chairman at HTNMS, United Kingdom Glioblastoma multiforme (GBM) is one of the most deadly cancers in humans. Despite recent advances in anti-cancer therapies, most patients with GBM die from local disease progression. Fluorescence image guided surgical resection (FIGR) was recently advocated to enhance local control of GBM. This is a meta-analysis of 5-aminolevulenic (5ALA) induced FIGR. Review of the literature produced 503 potential publications; only 20 of these fulfilled the inclusion criteria of this analyses, including a total of 565 patients treated with 5ALA-FIGR reporting on its outcomes and 800 histological samples reporting 5ALA-FIGR sensitivity and specificity. The mean gross total resection (GTR) rate was 75.4% (95%CI 67.4–83.5, p < 0.001). The mean time to tumor progression (TTP) was 8.1 months (95%CI 4.7–12, p < 0.001). The mean overall survival gain reported was 6.2 months (95%CI −1 to 13, p < 0.001). The specificity was 88.9% (95%CI 83.9–93.9, p < 0.001) and the sensitivity was 82.6% (95%CI 73.9–91.9, p < 0.001). 5ALA-FIGR in GBM is highly sensitive and specific, and imparts significant benefits to patients in terms of improved GTR, TTP, and overall survival. http://dx.doi.org/10.1016/j.pdpdt.2015.07.161
1
Department of Pulmonary and Critical Care medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Division of Thoracic Surgery, Republic of Korea 3 Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea 4 Division of Pulmonary, Allergy and Critical Care medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea Photodynamic therapy (PDT) is proven to be effective not only in early, superficial lung cancer but also in advanced lung cancer. Radachlorin® is a second generation photosensitizer with improved pharmacokinetics. Here, we report a case of advanced lung cancer successfully treated with PDT. A 16 year-old boy complained of cough and blood tinged sputum but chest X-ray showed no abnormal finding. Over 2 months, symptoms were aggravated and hemoptysis developed. CT scan displayed the complete luminal obstruction of right main bronchus near carina by mass lesion. Bronchoscopic biopsy confirmed undifferentiated carcinoma. PET scan showed left 8th rib metastasis. Because the tumor was very closely located near carina, surgery was not amenable. Therefore, photodynamic therapy with Radachlorin® (1 mg/kg on the day of PDT) was performed under the support extracorporeal membrane
The future of PDT/PD Brian C. Wilson 1 , Tayyaba Hasan 2 1 2
University of Toronto, Canada Harvard Medical School, USA
Photodynamic therapy (PDT) and diagnosis (PDD, including both diagnostics per se and fluorescence-guided therapeutics) have been a substantial focus for research and development for several decades, so it is timely to ask the questions: why are these techniques not more prominent in routine clinical practice?; why has there not been a “home run” in cancer as there was in PDT for age-related macular degeneration?, what roles might they evolve into?; what scientific, technological, regulatory, clinical, cultural, geographic and commercial challenges must be overcome to establish them as part of the oncologic armamentarium offered to patients? The purpose of this presentation is to stimulate discussion among the developers (physicists, engineers, chemists, materials scientists, biologists) to explore how to integrate their individual contributions into effective and cost-effective complete clinical solutions, between clinical specialists to determine the best indications for these techniques and how to interdigitate them with other established and emerging modalities, and between all players to get PDT and PDD deployed to the maximum possible benefit of patients. http://dx.doi.org/10.1016/j.pdpdt.2015.07.162